EUVIMEDEUVIMED entdecken
Crossref

LncRNA VCAN‐AS1 serves as a diagnostic biomarker and drives pathogenesis in diabetic nephropathy via the miR‐205‐5p/VEGFA axis

Jing Zhou, Shasha Li, Lingbo Lv, Guoxia Luo iD, Ning Xu

Diabetic Medicine · 2026-06 · 43 (6)

DOI: 10.1111/dme.70259 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetic Medicine, online erschienen am 19.03.2026. Verfasst von Jing Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Henan Clinical Medical Research Center for Nephropathy, Henan Provincial Key Laboratory of Kidney Disease and Immunology, H…. Hauptthemen laut MEDLINE: MicroRNAs, Diabetic Nephropathies, Vascular Endothelial Growth Factor A, RNA, Long Noncoding. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Technology Attack Plan Project of Henan Province, Medical Science and Technology Attack Plan Project of Henan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Diabetic nephropathy (DN) represents a major complication of diabetes mellitus (DM) with limited early diagnostic biomarkers. This study investigated the clinical significance and molecular mechanism of long non‐coding RNA (lncRNA) VCAN‐AS1 in DN pathogenesis.

Methods

The patients with diabetes mellitus, including 85 with DN and 66 without nephropathy, were enrolled, along with 62 healthy controls. Serum VCAN‐AS1 levels were detected using qRT‐PCR. Clinical parameters and renal injury markers were analysed for correlations with VCAN‐AS1. In vitro, high glucose‐treated human renal tubular cells (HK‐2) underwent genetic interventions including VCAN‐AS1 knockdown and miR‐205‐5p inhibition. Functional assessments encompassed cell viability, oxidative stress, fibrosis and inflammation. Dual‐luciferase reporter assays validated molecular interactions.

Results

Serum VCAN‐AS1 expression showed a progressive increase across healthy controls, diabetes mellitus patients and DN patients. It exhibited strong diagnostic efficacy for DN with an AUC of 0.879. Elevated VCAN‐AS1 correlated with deteriorated renal function parameters. VCAN‐AS1 was identified as an independent risk factor for diabetes mellitus progression to DN. High glucose exposure up‐regulated VCAN‐AS1 in HK‐2 cells, promoting cellular injury phenotypes. Rescue experiments confirmed that miR‐205‐5p inhibition reversed the protective effects of VCAN‐AS1 knockdown. Mechanistically, VCAN‐AS1 directly bound miR‐205‐5p, suppressing its expression and consequently enhancing vascular endothelial growth factor A (VEGFA) expression.

Conclusions

VCAN‐AS1 serves as a potential diagnostic biomarker for DN and promotes disease pathogenesis through the miR‐205‐5p/VEGFA axis, highlighting its potential as a therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsDiabetic NephropathiesVascular Endothelial Growth Factor ARNA, Long NoncodingHumansMaleBiomarkersFemaleMiddle AgedCase-Control StudiesDisease Progression

Stichwörter der Autor:innen

VCAN‐AS1VEGFAbiomarkerdiabetic nephropathykidney dysfunctionmiR‐205‐5p

Substanzen

MicroRNAsMIR205, humanBiomarkersVascular Endothelial Growth Factor ARNA, Long NoncodingVEGFA protein, human

Autor:innen und Institutionen

  • Department of Nephrology, Henan Clinical Medical Research Center for Nephropathy, Henan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial People's Hospital, Zhengzhou University People's Hospi…
  • Department of Endocrinology, The People's Hospital of Kaizhou District, Chongqing, China.
  • Department of Endocrinology, Shenzhen Second People's Hospital, Shenzhen, Guangdong, China.
  • Department of Medical Laboratory Medicine, Chongqing University Fuling Hospital, Chongqing, China.
  • Department of Endocrinology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine; National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.

ORCID-Profile: Guoxia Luo

Förderung

  • Technology Attack Plan Project of Henan Province
  • Medical Science and Technology Attack Plan Project of Henan Province

Zitieren

APA

Zhou, J., Li, S., Lv, L., Luo, G., & Xu, N. (2026). LncRNA VCAN‐AS1 serves as a diagnostic biomarker and drives pathogenesis in diabetic nephropathy via the miR‐205‐5p/VEGFA axis. Diabetic Medicine, 43(6). https://doi.org/10.1111/dme.70259

Vancouver

Zhou J, Li S, Lv L, Luo G, Xu N. LncRNA VCAN‐AS1 serves as a diagnostic biomarker and drives pathogenesis in diabetic nephropathy via the miR‐205‐5p/VEGFA axis. Diabetic Medicine. 2026;43(6). doi:10.1111/dme.70259

BibTeX
@article{Zhou2026,
  author = {Zhou, Jing and Li, Shasha and Lv, Lingbo and Luo, Guoxia and Xu, Ning},
  title = {LncRNA VCAN‐AS1 serves as a diagnostic biomarker and drives pathogenesis in diabetic nephropathy via the miR‐205‐5p/VEGFA axis},
  journal = {Diabetic Medicine},
  year = {2026},
  volume = {43},
  number = {6},
  doi = {10.1111/dme.70259}
}
Kostenlos starten →